^
    Apply
    A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer (NCT03471663)
    Phase 1
    InventisBio Co., Ltd
    Completed
    Last update posted :
    01/08/2024
    Initiation :
    03/18/2018
    Primary completion :
    10/18/2023
    Completion :
    10/18/2023
    HER-2 • ER
    |
    ER positive • HER-2 negative
    |
    Ibrance (palbociclib) • taragarestrant (D-0502)